Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527916 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 438
- Enrollment target
NCT01527916 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 438 participants.
The verdict
NCT01527916, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 438 participants
- Enrollment target
Study Summary
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
Interventions
- DRUG placebo
- DRUG ABT-126
- DRUG donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01527916
The ClinicalTrials.gov registry entry for NCT01527916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01527916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01527916 about?
NCT01527916 is a clinical study titled "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease". This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT01527916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2012-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01527916?
The interventions under investigation include: placebo (DRUG), ABT-126 (DRUG), donepezil (DRUG).
Who is sponsoring clinical trial NCT01527916?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.